Abstract:RATIONALE & OBJECTIVE: <AbstractText Label="RATIONALE &amp; OBJECTIVE">Challenges in achieving valid risk prediction and stratification impede treatment decisions and clinical research design for patients with glomerular diseases. This study evaluated whether chronic histologic changes, when complementing other clinical data, improved the prediction of disease outcomes across a diverse group of glomerular diseases.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN">Multicenter retrospective cohort study.</AbstractText>SETTING & PARTICIPANTS: <AbstractText Label="SETTING &amp; PARTICIPANTS">4,982 patients with biopsy-proven glomerular disease who underwent native biopsy at 8 tertiary care hospitals across China in 2004-2020.</AbstractText>NEW PREDICTORS & ESTABLISHED PREDICTORS: <AbstractText Label="NEW PREDICTORS &amp; ESTABLISHED PREDICTORS">Chronicity scores depicted as 4 categories of histological chronic change, as well as baseline clinical and demographic variables.</AbstractText>OUTCOME: <AbstractText Label="OUTCOME">Progression of glomerular disease defined as a composite of kidney failure or a ≥40% decrease in estimated glomerular filtration rate from the measurement at the time of biopsy.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH">Multivariable Cox proportional hazard models. The performance of predictive models was evaluated by C statistic, time-dependent area under the receiver operating characteristic curve (AUROC), net reclassification index, integrated discrimination index, and calibration plots.</AbstractText>RESULTS: <AbstractText Label="RESULTS">The derivation and validation cohorts included 3,488 and 1,494 patients, respectively. During a median of 31 months of follow-up, a total of 444 (8.9%) patients had disease progression in the 2 cohorts. For prediction of the 2-year risk of disease progression, the AUROC of the model combining chronicity score and the Kidney Failure Risk Equation (KFRE) in the validation cohort was 0.76 (95% CI, 0.65-0.87); in comparison with the KFRE model (AUROC, 0.68 [95% CI, 0.56-0.79]), the combined model was significantly better (P = 0.04). The combined model also had a better fit, with a lower Akaike information criterion and a significant improvement in reclassification as assessed by the integrated discrimination improvements and net reclassification improvements. Similar improvements in predictive performance were observed in subgroup and sensitivity analyses.</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS">Selection bias, relatively short follow-up, lack of external validation.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Adding histologic chronicity scores to the KFRE model improved the prediction of kidney disease progression at the time of kidney biopsy in patients with glomerular diseases.</AbstractText>PLAIN-LANGUAGE SUMMARY: <AbstractText Label="PLAIN-LANGUAGE SUMMARY">Risk prediction and stratification remain big challenges for treatment decisions and clinical research design for patients with glomerular diseases. The extent of chronic changes is an important component of kidney biopsy evaluations in glomerular disease. In this large multicenter cohort including 4,982 Chinese adults undergoing native kidney biopsy, we evaluated whether histologic chronicity scores, when added to clinical data, could improve the prediction of disease prognosis for a diverse set of glomerular diseases. We observed that adding histologic chronicity scores to the kidney failure risk equation improved the prediction of kidney disease progression at the time of kidney biopsy in patients with glomerular diseases.</AbstractText>

Variations in Laboratory Parameters in Prechronic Disease to Determine Disease Occurrence at the Molecular Level

Biological and Analytical Variations of 16 Parameters Related to Coagulation Screening Tests and the Activity of Coagulation Factors

Biological and analytical variations of 16 parameters related to coagulation screening tests and the activity of coagulation factors.

Biological Variation in 32 Clinical Laboratory Routine Tests

Biological Variations of Hematologic Parameters Determined by UniCel DxH 800 Hematology Analyzer.

Intra-day and Inter-Day Biological Variations of Peripheral Blood Lymphocytes.

A comprehensive repository of mutation data and a clinical assistant decision system for hemoglobinopathy in the Chinese population

Gene expression ranking change based single sample pre-disease state detection

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

The impact of physiological variations on personalized reference intervals and decision limits: an in-depth analysis

Investigation of Variation in Gene Expression Profiling of Human Blood by Extended Principle Component Analysis.

Biological Variations of Lupus Anticoagulant, Antithrombin, Protein C, Protein S, and von Willebrand Factor Assays.

Diagnosis Based on Population Data versus Personalized Data: The Evolving Paradigm in Laboratory Medicine

Use of Histologic Parameters to Predict Glomerular Disease Progression: Findings From the China Kidney Biopsy Cohort Study

The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples

Short-term Biological Variation of Glycated Hemoglobin-A1 c

Biomarker Changes during 20 Years Preceding Alzheimer's Disease

Use biological variation to value the lower detect limit of hematology and platelet aggregation test

A consensus on the standardization of the next generation sequencing process for the diagnosis of genetic diseases (1)-Procedures prior to genetic testing

Objective Assessment of Health or Pre-Chronic Disease State Based on a Health Test Index Derived from Routinely Measured Clinical Laboratory Parameters

Clinical laboratory tests and dementia incidence: A prospective cohort study